- Home
- PRZO vs NRSN Comparison
PRZO vs NRSN Comparison
Compare PRZO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | NRSN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Israel | Israel |
| Employees | N/A | 15 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 28.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRZO | NRSN |
|---|---|---|
| Price | $1.28 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 562.7K | 136.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.68 |
| 52 Week High | $2.15 | $2.60 |
Technical Indicators
Market Signals| Indicator | PRZO | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 44.64 |
| Support Level | $1.11 | $0.85 |
| Resistance Level | $1.48 | $1.30 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 70.93 | 19.12 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.